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Curcumin, a curcuminoid from Curcuma longa, presents antioxidant and anti-inﬂammatory actions and,
among pathological changes of cerebral ischemic injury, inﬂammation is an important one. The objec-
tives were to study the neuroprotective action of curcumin, in a model of global ischemia. Male Wistar
rats (sham-operated, ischemic untreated and ischemic treated with curcumin, 25 or 50 mg/kg, p.o.) were
anesthesized and their carotid arteries occluded, for 30 min. The SO group had the same procedure,
except for carotid occlusion. In the 1st protocol, animals were treated 1 h before ischemia and 24 h later;
and in the 2nd protocol, treatments began 1 h before ischemia, continuing for 7 days. Twenty four hours
after the last administration, animals were euthanized and measurements for striatal monoamines were
performed, at the 1st and 7th days after ischemia, as well as histological and immunohistochemical assays
in hippocampi. We showed in both protocols, depletions of DA and its metabolites (DOPAC and HVA), in
the ischemic group, but these effects were reversed by curcumin. Additionally, a decrease seen in 5-HT
contents, 1 day after ischemia, was also reversed by curcumin. This reversion was not seen 7 days later.
On the other hand, a decrease observed in NE levels, at the 7th day, was totally reversed by curcumin.
Furthermore, curcumin treatments increased neuronal viability and attenuated the immunoreactivity for
COX-2 and TNF-alpha, in the hippocampus in both protocols. We showed that curcumin exerts neuro-
protective actions, in a model of brain ischemia that are probably related to its anti-inﬂammatory
activity.
Copyright © 2016, Center for Food and Biomolecules, National Taiwan University. Production and hosting
by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Curcumin is the major chemical component of turmeric, pro-
duced from the rhizome of Curcuma longa, a traditional plant0/1100, 60170-020, Fortaleza,
(G.F.T. de Alca^ntara),
ruz@hotmail.com (G.M.P. da
hotmail.com (K.R.T. Neves),
com (G.A.C. Brito), gbviana@
for Food and Biomolecules,
molecules, National Taiwan Unive
ons.org/licenses/by-nc-nd/4.0/).belonging to the Zingiberaceae family and used in Ayurvedic
medicine for over 6,000 years. Curcumin is a polyphenol that
possesses anti-inﬂammatory, antioxidant, antidiabetic, anticarci-
nogenic properties, among others.
Brain ischemia is a condition that occurs when there is not
enough blood ﬂow to the brain for meeting metabolic demands.
This leads to limited oxygen supply or cerebral hypoxia and often to
the death of brain tissues, cerebral infarction, or ischemic stroke.
Stroke is currently the second most common cause of death and
major cause of disability worldwide. Because of the aging popula-
tion, the burden will greatly increase during the next 20 years.1
However, stroke recently declined in the USA from the third to
the fourth leading cause of death.2rsity. Production and hosting by Elsevier Taiwan LLC. This is an open access article
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blood ﬂow (CBF) after cardiac arrest, the occlusion of cerebral and
extracerebral vessels supplying nervous tissues, or periods of pro-
longed systemic hypotension. Severe and/or prolonged reduction in
CBF leads to deprivations of oxygen and glucose, as well as to the
building up of potentially toxic substances. Because nerve cells do
not store alternative energy sources, these hemodynamic re-
ductions can result in the reduction of metabolites, as ATP, leading
tometabolic stress, energy failure, ionic perturbations and ischemic
injury.3
Cells that undergo severe ischemia may die within minutes of
the insult or display a delayed vulnerability. Ischemic insults can be
focal or global, as well as permanent or transient ones, leading to
reperfusion in post-ischemia areas. Depending on how early
reperfusion is initiated, metabolic and ionic homeostases can re-
turn and cell survival maintained.4
Both necrotic and apoptotic cell death mechanisms have been
implicated in the pathogenesis of brain ischemia injury.5e8 The
brain is vulnerable to oxidative stress, due to its high rate of
oxidative metabolic activity.9 Oxidative stress, leading to calcium
accumulation, mitochondrial dysfunction and the production of
reactive oxygen radicals, is an important mechanism of cell death,
following brain ischemia.10,11
Inﬂammation is a host defense mechanism initiated by injury,
through which blood leukocytes and soluble factors, as cytokines,
chemokines, complement and lipid by-products attempt to restore
tissue homeostasis.12 Inﬂammation plays an important role in the
pathogenesis of ischemic brain injury. Experimental and clinical
studies have shown that the brain responds to ischemic injury with
an acute and prolonged inﬂammatory process, characterized by
rapid activation of resident cells, as microglia, production of in-
ﬂammatory mediators and inﬁltration of inﬂammatory cells into
the brain ischemic tissue.13
Considering that curcumin presents anti-inﬂammatory and
antioxidative properties, as shown by us14 and others,15,16 and the
importance of inﬂammation and oxidative stress in brain injury, the
objectives of the present workwere to evaluate the neuroprotective
effects of curcumin on neurochemical (striatal DA and DOPAC)
determinations and on histological (ﬂuoro-jade staining) and
immuno-histochemical (COX-2 and TNF-alpha) assays in the hip-
pocampus, in the model of global ischemia in rats.
2. Material and methods
2.1. Drugs
Commercial curcumin was purchased from Sigma-Aldrich (MO,
USA) and presented 94% of curcuminoid content and 80% of
curcumin. Ketamine and xylazine were from Konig Laboratory
(Santana de Parnaíba, S~ao Paulo, Brazil). Antibodies for immuno-
histochemistry assays were from Santa Cruz Biotechnology (Dallas,
TX, USA) or Merck-Millipore (Darmstadt, Germany). All other re-
agents were of analytical grade.
2.2. Animals and experimental protocols
Male Wistar rats from the Animal House of the Faculty of
Medicine Estacio of Juazeiro do Norte, Brazil, were maintained
under standard conditions and at a controlled temperature
(23 ± 1 C), with a 12 h dark/12 h light cycle, and food and water ad
libitum. The animals (4e10 per group) were divided into four
groups: controls treated with distilled water (SO and ischemic
untreated with curcumin) or treated orally with curcumin (from
Sigma-Aldrich, USA), at the doses of 25 or 50 mg/kg. Two protocols
were used. In the 1st one, the animals were subjected to ischemiaand treated 1 h before ischemia and 24 h later, and they were
euthanized, 1 h after the drug second administration. In the 2nd
protocol, the animals were subjected to ischemia, but daily treat-
ments began 1 h before ischemia and continued, at the next day,
daily for 7 days. For the experimental procedure, the rats were
anesthetized with ketamine (100 mg/kg, i.p.) and xylazine (20 mg/
kg), then submitted or not (SO groups) to transient global brain
ischemia by the occlusion of the left common carotid artery, for
30 min, followed by reperfusion. The sham-operated groups (SO)
were submitted to the entire procedure, except for the artery oc-
clusion. Twenty four hours after the last drug administration, the
animals were euthanized for dissection of striata and hippocampi.
Neurochemical alterations (DA and DOPAC determinations in
striata) were assessed, at the 1st and 7th days after ischemia. Be-
sides, immunohistochemical assays in hippocampi were also per-
formed, at those same periods. The study had the approval of the
Animal Experimentation Committee of the Federal University of
Ceara and the experiments were carried out in accordance with the
current law and the NIH Guide for the Care and Use of Laboratory
Animals, 2011.
3. Neurochemical assays
3.1. Concentrations of striatal monoamine (NE, DA, DOPAC, 5-HT
and HVA) by HPLC
The striata from all groups, at different post-ischemia times,
were used for the preparation of 10% homogenates in 0.1 M
perchloric acid. This mixture was sonicated for 30 s, centrifuged at
4 C for 15 min, at 15,000 rpm. The supernatants were ﬁltered
(0.2 mm, Millipore) and 20 mL injected into the HPLC column (Shim-
Pack CLC-ODS, 25 cm) for electrochemical detection (Shimadzu,
model LCD-6A, Japan), with a 0.6 mL/min ﬂux. The mobile phase
was prepared in 0.163 M citric acid, pH 3.0, containing 0.02 mM
EDTA and 0.69 mM sodium octanosulfonic acid, 4% acetonitrile (v/
v) and 1.7% tetrahydrofuran (v/v). Monoamine concentrations were
determined by comparison to standards and the values expressed
as ng/mg tissue.
3.2. Histological study for neuronal viability (ﬂuoro-jade staining)
Fluoro-jade is an anionic ﬂuorescein derivative, useful for the
histological staining of neurons undergoing degeneration. After
parafﬁn removal (by immersion in xylol), sections (5 mm) from
hippocampi were mounted on slides surrounded by gelatin. The
tissue was rehydrated by immersion in ethanol for 3 min, followed
by immersions in 70 and 50% ethanol solutions and distilled water.
The slices were placed into a 0.06% potassium permanganate so-
lution, for 15 min, washed in distilled water and transferred to a
ﬂuoro-jade solution where they stayed for 30 min (with gentle
stirring). After staining, the slices were washed in distilled water (3
times, 2 min each time). The excess of water was discarded and the
dry slices mounted in Fluoromount® media and examined with a
ﬂuorescencemicroscope. The datawere quantiﬁed with the Image J
software (National Institute of Health, USA).
3.3. Immunohistochemical assays for COX-2 and TNF-alpha in rat
hippocampi
Sections were ﬁxed in 10% buffered formol, for 24 h, followed by
immersion in a 70% alcohol solution. They were embedded into
parafﬁnwax, for slices processing on appropriate glass slides. These
were placed into the oven at 58 C, for 10 min, followed by
deparafﬁnization in xylol, rehydration in alcohol at decreasing
concentrations, washing in distilled water and PBS (0.1 M sodium
G.F.T. de Alca^ntara et al. / Journal of Traditional and Complementary Medicine 7 (2017) 14e2316phosphate buffer, pH 7.2) for 10 min. The endogenous peroxidase
was blocked with a 3% hydrogen peroxide solution, followed by
incubation with appropriate primary anti-antibodies, diluted ac-
cording to the manufacturers' instructions (Santa Cruz or Millipore,
USA), for 2 h, at room temperature in a moist chamber. The glass
slides were then washed with PBS (3 times, 5 min each) and
incubated with the biotinylated secondary antibody, for 1 h, at
room temperature in the moist chamber. Then, they were washed
again in PBS and incubated with streptavidin-peroxidase, for
30 min, at room temperature, again in a moist chamber. After
another wash in PBS, they were incubated in 0.1% DAB solution (in
3% hydrogen peroxide). Finally, the glass slides were washed in
distilled water, dehydrated in alcohol (at increasing concentra-
tions), diaphanized in xylol and mounted on Entelan® for optic
microscopy examination. The datawere quantiﬁed with the Image J
software (National Institute of Health, USA).4. Statistical analyses
For statistical analyses, One-way ANOVA, followed by the
NewmaneKeuls as the post hoc test for multiple comparisons were
used. Whenever needed, the paired or unpaired Student's t-testFig. 1. Curcumin treatments reverse DA and its metabolites, DOPAC and HVA, as well as NE a
after ischemia. DA: a. vs. SO, q ¼ 3.220; b. vs. ISC þ C25, q ¼ 12.49; c. vs. ISC þ C50, q ¼ 3.8
ISC þ C25, q ¼ 4.269; c. vs. ISC þ C50, t ¼ 2.858, df ¼ 8; d. vs. SO, q ¼ 4.957. HVA: a. vs. SO, q ¼
vs. ISC þ C25, t ¼ 2.800, df ¼ 7; c. vs. SO, q ¼ 8.425; d. vs. SO, q ¼ 7.383. 5-HT: a. vs. SO, q ¼
followed by NewmaneKeuls as the post hoc test and two-tailed unpaired t-test).was used for comparisons between two means. Differences were
considered signiﬁcant at p < 0.05.5. Results
5.1. Determination of monoamine contents in striatal tissue from
ischemic rats, after 1 and 7 post-ischemia days
Our results demonstrated that all the monoamine striatal con-
centrations decreased (39 to 67%) in the untreated ischemic group,
as related to the SO group, at 1 post-ischemia day (Fig. 1A, B, C and
D). Except in the case of NE contents, where the decreases in the
untreated ischemic group were maintained, these alterations were
totally (e.g. DA, HVA and 5-HT) or partially (DOPAC) reversed in the
curcumin (25 and 50mg/kg) treated ischemic groups. As far as DA is
concerned, its levels in the curcumin treated ischemic groups were
even higher than those in the SO group, mainly after the lower
curcumin dose (2.1-fold increase). The pattern of changes, at the 7th
post-ischemia day, was different as related to that observed in the
1st post-ischemia day. Thus, while signiﬁcant decreases were seen
in NE (58%) and DA (25%) contents in the untreated ischemic group,
no signiﬁcant changes were observed in the levels of othernd 5-HT alterations, as related to the curcumin-untreated ischemic group, at the 1st day
57; d. vs. SO, q ¼ 9.269; e. vs. ISC þ C25, q ¼ 7.097. DOPAC: a. vs. SO, q ¼ 7.487; b. vs
6.256; b. vs. ISC þ C25, q ¼ 4.167; c. vs. ISC þ C50, q ¼ 6.971. NE: a. vs. SO, q ¼ 5.629; b.
4.649; b. vs. ISC þ C25, q ¼ 4.101; c. vs. ISC þ C50, t ¼ 3.976, df ¼ 12 (One-way ANOVA
G.F.T. de Alca^ntara et al. / Journal of Traditional and Complementary Medicine 7 (2017) 14e23 17monoamines, as related to the SO group. These changeswere totally
reversed in the ischemic group after curcumin treatments. Inter-
estingly, in this protocol (7th post-ischemia day), 5-HT contents
were similar in all groups tested (Fig. 2A, B, C, D).
5.2. Fluoro-jade staining in rat hippocampi
Fig. 3 are photomicrographs of sham operated (SO), untreated
ischemic groups and ischemic groups after curcumin treatments
(25 and 50 mg/kg), at 1 day after ischemia. The data show lower
neuron viabilities in the CA1, CA3, DG and temporal cortex (TC) of
the untreated ischemic group, as related to those of the SO group.
However, changes were observed mainly in the CA1 and DG areas
which showed 45 and 55% reductions in neuron viability, respec-
tively, as related to the SO group. The ischemic groups after treat-
ments with curcumin presented a proﬁle similar to those of the SO
group. Fig. 4 presents the same areas in the 2nd protocol (7th day
after ischemia). Lower neuron viabilities were seen in the untreated
ischemic group, mainly at CA1 and TC areas (52 and 69% reductions,
respectively, as related to the SO group) and these changes were
completely reversed after curcumin treatments.
5.3. Immunohistochemistry assays for COX-2 and TNF-alpha in rat
hippocampi
Fig. 5 shows immunohistochemistry assays for COX-2, an
inducible inﬂammatory enzyme. A higher immunostaining wasSO ISC
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Fig. 2. Curcumin treatments partly reversed DA and its metabolites, DOPAC and HVA, as we
the 7th day after ischemia. DA: a. vs. SO, t ¼ 2.306, df ¼ 11; b. vs. ISC þ C50, q ¼ 6.551; c. vs. IS
a. vs. SO, t ¼ 2.986, df ¼ 14; b. vs. SO, t ¼ 3.043, df ¼ 9; c. vs. SO, t ¼ 2.445, df ¼ 11. NE: a.
ISC þ C25, q ¼ 5.565; e. vs. SO, q ¼ 5.222 (One-way ANOVA followed by NewmaneKeuls aobserved in the TC area in the untreated ischemic groups, at 1 and
7 days after ischemia. This effect was drastically decreased in the
ischemic group after curcumin treatments (25 and 50 mg/kg). A
much higher immunostaining for TNF-alpha, a pro-inﬂammatory
cytokine, was also demonstrated in CA1 (5.5-fold), CA3 (19-fold)
and hilus (12.7-fold) in the untreated ischemic group, as related
to the SO groups. These values were drastically attenuated in the
ischemic group after curcumin treatments (25 and 50 mg/kg), at
the 1st day after ischemia (Fig. 6). At the 7th post-ischemia day,
the untreated ischemic group showed a 20-fold increase in TNF-
alpha immunoreactivity, in both CA1 and CA3 areas, and only a
4.4-fold increase in the hylus, as related to the SO group. Similarly,
immunostainings for TNF-alpha were highly attenuated after
curcumin treatments, emphasizing the involvement of this cyto-
kine in the neuroprotective effect of curcumin (Fig. 7).6. Discussion
Curcuma longa is probably one of the most studied medicinal
plants and presents curcumin as its main bioactive compound.
Curcumin shows a great number of biological effects, ranging from
anti-inﬂammatory to anticancer properties, among several
others.17,18 More recently, several studies have shown the neuro-
protective effects of curcumin in animal models of brain
ischemia.15,19e23 In addition, it is largely accepted that inﬂamma-
tion plays an important role in brain ischemia.13 Lastly, curcuminSO ISC
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C þ C50, q ¼ 3.994; d. vs. SO, q ¼ 3.949. DOPAC: a. vs. ISC þ C50, t ¼ 2.225, df ¼ 12. HVA:
vs. SO, q ¼ 5.124; b. vs. ISC þ C25, t ¼ 2.384, df ¼ 8; c. vs. ISC þ C50, q ¼ 10.85; d. vs.
s the post hoc test and two-tailed unpaired t test).
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different disorders, including neurological diseases.24
Evidences from in vitro and in vivo experimental as well as
clinical studies indicate that the brain responds to ischemic injury
with an acute and prolonged inﬂammatory process, characterized
by rapid activation of resident cells, production of proinﬂammatory
mediators and inﬁltration of inﬂammatory cells into the ischemic
brain tissue.13,25e27 The brain is particularly vulnerable to ischemia
and the interruption of blood ﬂow to the brain, even for a short
period of time, as 5 min, triggers the death of neurons in several
brain regions.28 The severe and prolonged reduction of cerebral
blood ﬂow leads to deprivations in oxygen and glucose, as well as to
the increase of potentially toxic substances.4
In the present study, we showed that brain ischemia signiﬁ-
cantly decreases not only striatal DA contents, but also its me-
tabolites (DOPAC and HVA). Although this effect was observed
mainly at the 1st day after ischemia, it was still seen 7 days later.
Earlier studies demonstrated that, during brain ischemia, the
blood ﬂow decreased up to 95%, but recovered to control levels
during reperfusion.29 These authors showed that dopamine
increased markedly in the cerebral cortex and striatum, during
recirculation, while its metabolites DOPAC and HVA were notFig. 3. Representative photomicrographs (400 magniﬁcation) of ﬂuoro-jade staining, in th
the untreated ischemic group, as related to the SO group. Alterations were mainly seen at
areas, and the optical density values were brought towards those of the SO group. The dat
q ¼ 23.29; c. vs. ISC þ C50, q ¼ 22.70. CA3: a. vs. SO, q ¼ 14.36; b. vs. ISC þ C25, q ¼ 18.93
ISC þ C50, q ¼ 15.80. TC: a. vs. SO, q ¼ 17.41; b. vs. ISC þ C25, q ¼ 13.92; c. vs. ISC þ C50,much affected. This massive increase in DA was observed in the
hippocampus as well.30 Others,31,32 showed that the marked in-
crease in extracellular levels of DA in the striatum persisted
throughout ischemia and was rapidly cleared up during reperfu-
sion, mainly via reuptake.
Recently,33 the extracellular concentration of DA was shown to
increase abruptly, 3 min after the ischemic insult, reaching a
maximum after 20e40 min and decreasing subsequently. For
120 min, DOPAC and HVA concentrations also decreased signiﬁ-
cantly. These data indicated that a large increase of extracellular DA
concentration, in cerebral ischemia, probably results from energy
failure of cell membranes andmight play a role in neuronal damage
associated to cerebral ischemia. In our study, all monoamine
measurements were performed several hours or several days after
ischemia and the initial increase in these monoamine contents was
replaced by a signiﬁcant decrease instead, particularly because, in
our case, we used a transient brain ischemia model. This result was
similar to other ones,34 showing that, after different time intervals,
ranging from 24 up to 96 h, DA and its metabolites in the striatum
decreased markedly, as related to control values.
In the present study, most of these alterations in monoamine
contents were reversed in the ischemic group after curcumine CA1, CA3, DG and TC areas, at 1 day after ischemia, showing lower neuron viability in
the CA1 area. The curcumin treatments signiﬁcantly improved neuronal viability in all
a were quantiﬁed by the Image J software. CA1: a. vs. SO, q ¼ 24.19; b. vs. ISC þ C25,
; c. vs. ISC þ C50, q ¼ 14.40. DG: a. vs. SO, q ¼ 15.64; b. vs. ISC þ C25, q ¼ 11.89; c. vs.
q ¼ 16.83 (One-way ANOVA and NewmaneKeuls as the post hoc test).
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and 7th days after ischemia that were reversed only after a 7-day
treatment of the ischemic group. While no changes were
observed in 5-HT levels, 7 days after ischemia, a decrease had
occurred at the 1st post-ischemia day and this effect was
completely reversed by curcumin treatments. Thus, we showed a
different proﬁle in NE and 5-HT contents in the striatum, after
ischemia and curcumin treatments. Curcumin was shown35e37 to
increase DA levels and to cause no change in NE, when combined to
antidepressant drugs, and this effect could at least partly be
involved with the curcumin antidepressant effect. This antide-
pressant effect of curcumin seems to involve not only 5-HT but also
dopamine systems.38
Although, in the present study, besides much lower neuron
viability, we also showed a high immunoreactivity in almost all
hippocampal areas of the untreated ischemic group that was in
great part blocked in the ischemic group after curcumin treatments.
These results were observed for COX-2 and TNF-alpha. Inﬂamma-
tory processes are very important in the pathophysiology of stroke
where a key initial event is the activation of microglia.39 Further-
more, in vitro studies demonstrate that curcumin reduces the
production of ROS and inﬂammatory mediators from activatedFig. 4. Representative photomicrographs (400 magniﬁcation) of ﬂuoro-jade staining, in th
neuron viability in the untreated ischemic group, as related to the SO group. Alterations w
improved neuronal viability in all areas, and the optical density values were brought toward
SO, q ¼ 14.47; b. vs. ISC þ C25, q ¼ 14.37; c. vs. ISC þ C50, q ¼ 14.02. B-CA3: a. vs. SO, q ¼ 7
ISC þ C25, q ¼ 5.353. C-DG: a. vs. SO, q ¼ 103.3; b. vs. ISC þ C25, q ¼ 81.56; c. vs. ISC þ C50, q
ISC þ C25, q ¼ 29.43; c. vs. ISC þ C50, q ¼ 33.78; d. vs. SO, q ¼ 6.103; e. vs. ISC þ C50, q ¼microglia.40 Microglial cells are important effectors of the neuronal
innate immune system, and in vitro studies show that curcumin
attenuates microglial migration, triggering a cell phenotype with
anti-inﬂammatory and neuroprotective properties.41 These data
agree with ours, suggesting of a curcumin neuroprotective action.
The anti-inﬂammatory effect of curcumin is likely mediated
through its ability to inhibit not only COX-2, but also LOX and ions,
important enzymes that mediate inﬂammatory processes. Indeed,
at cellular and molecular levels, curcumin has been shown to
regulate signaling pathways involving COX and LOX.42,43 In the
present study, we showed that the curcumin treatment of ischemic
animals decreases COX-2 immunostaining in hippocampal areas, as
related to the curcumin-untreated ischemic group, what points out
to its anti-inﬂammatory property.
Earlier studies in rats44 showed that focal cerebral ischemia
results in elevated TNF-alpha mRNA, in ischemic neurons. TNF-
alpha is a pleiotrophic polypeptide, known to play a signiﬁcant
role in brain immune and inﬂammatory activities.45 It is produced
in the brain in response to various pathological processes, including
ischemia.
Others46 showed that exogenous TNF-alpha exacerbates focal
ischemic injury, thus the blocking of TNF-alpha is neuroprotective.e CA1 (A), CA3 (B), DG (C) and TC (D) areas, at 7 days after ischemia, showing lower
ere observed mainly at the CA1 and TC areas. The curcumin treatments signiﬁcantly
s those of the SO group. The data were quantiﬁed by the Image J software. A-CA1: a. vs.
.511; b. vs. ISC þ C25, q ¼ 14.44; c. vs. ISC þ C50, q ¼ 9.092; d. vs. SO, q ¼ 6.9.34; e. vs.
¼ 105.8; d. vs. SO, q ¼ 21.78; e. vs. ISC þ C50, q ¼ 24.20. D-TC: a. vs. SO, q ¼ 35.08; b. vs.
4.695 (One-way ANOVA and NewmaneKeuls as the post hoc test).
Fig. 5. Representative photomicrographs showing less immunostaining for COX-2 in the temporal cortex (TC) area, in the ischemic group after curcumin treatments, as related to
curcumin-untreated ischemic animals, at the 1st and 7th post-ischemia days (x400). The data were quantiﬁed by the Image J software and the results expressed as optical densities.
TC, 1day: a. vs. ISC þ C25, q ¼ 13.27; b. vs. ISC þ C50, q ¼ 16.01. TC, 7 days: a. vs. ISC þ C25, q ¼ 13.74; b. vs. ISC þ C50, q ¼ 14. 57 (One-way ANOVA and NewmaneKeuls as the post
hoc test).
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pharmacological strategy to treat brain ischemia and related pro-
cesses. More recently, curcuminwas found to inhibit the expression
of TNF-alpha-induced IL-1beta and IL-6, in HaCaT cells.47 These
authors concluded that curcumin exerts anti-inﬂammatory and
growth inhibitory effects in TNF-alpha-treated HaCaT cells, through
inhibition of NF-kappa B and MAPK pathways.
Curcumin was shown to block the activation of NF-kappa B by
TNF-alpha, in human endothelial cells.48 More recently,49evidences from a review study indicate that curcumin blocks
TNF-alpha production in vitro and in vivo models, as well as in
humans, and is active against all diseases for which TNF-alpha
blockers are currently being used. Clinical studies indicate that
inﬂammatory processes are associated with the early stage of
ischemic stroke, and TNF-alpha and IL-6 are higher in patients with
a bad prognostic.50
Despite concerns about its poor oral biodisponibility, curcumin
has been shown to present at least ten neuroprotective actions.25
Fig. 6. Representative photomicrographs (100 magniﬁcation) showing a high immunoreactivity for TNF-alpha in CA1, CA3 and hilus areas, in the untreated ischemic group, as
related to the SO group, at 1 day after ischemia. The effects were more intense in the CA3 area which showed a 19-fold increase in TNF-alpha immunoreactivity. The curcumin
treatment completely reversed these effects, which were quantiﬁed by the Image J software. CA1: a. vs. SO, q ¼ 9.887; b. vs. ISC þ C25, q ¼ 8.775; c. vs. ISC þ C50, q ¼ 9.804. CA3: a.
vs. SO, q ¼ 12.23; b. vs. ISC þ C25, q ¼ 8.501; c. vs. ISC þ C50, q ¼ 12.44; d. vs. SO, q ¼ 3.727; e. vs. ISC þ C50, q ¼ 3.942. Hilus: a. vs. SO, q ¼ 18.64; b. vs. ISC þ C25, q ¼ 19.36; c. vs.
ISC þ C50, q ¼ 20.16 (One-way ANOVA and NewmaneKeuls as the post hoc test).
G.F.T. de Alca^ntara et al. / Journal of Traditional and Complementary Medicine 7 (2017) 14e23 21Thus, we feel that curcumin and/or its more stable metabolite,
tetrahydrocurcumin (TC), are responsible for the observed effects
shown by us. A previous study51 clearly demonstrated the anti-
oxidant, anti-inﬂammatory and anti-amyloidogenic effects of di-
etary curcumin and TC, chronically or acutely administered on
LPS-injected mice. These authors showed that, despite higher
drug plasma levels after TC as compared to curcumin, the
resulting brain levels of parent compounds were similar and
correlated with the reduction in LPS-stimulated iNOS and other
endogenous compounds. Curcumin and TC also reduced chronic
inﬂammation and IL-1beta. In addition, TC was detected in mice
brain and plasma. Surprisingly, curcumin but not TC prevented Ab
aggregation in models of neuroinﬂammation and Alzheimer'sdisease. Furthermore, all these data support our ﬁndings and
indicate that curcumin and/or TC are responsible for the neuro-
protective properties.
7. Conclusion
We showed that curcumin reverses most of the neurochemical
and immunohistochemical alterations of the ischemic group.
Considering the involvement of inﬂammation in brain ischemic
episodes and the anti-inﬂammatory property of curcumin, as well
as its antioxidant activity observed even at lower doses, as shown
by us14 and others,42,52e54 our data emphasize the potential beneﬁt
of curcumin in the prevention or treatment of stroke.
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Fig. 7. Representative photomicrographs (100 magniﬁcation) showing a high immunoreactivity for TNF-alpha in CA1, CA3 and hilus areas, in the untreated ischemic group, as
related to the SO group, at 7 days after ischemia. The effects were more intense in CA1 and CA3 areas which showed a 20-fold increase in TNF-alpha immunoreactivity. The
curcumin treatment completely reversed these effects which were quantiﬁed by the Image J software. CA1: a. vs. SO, q ¼ 50.77; b. vs. ISC þ C25, q ¼ 53.44; c. vs. ISC þ C50,
q ¼ 53.44. CA3: a. vs. SO, q ¼ 22.45; b. vs. ISC þ C25, q ¼ 18.72; c. vs. ISC þ C50, q ¼ 23.52; d. vs. SO, q ¼ 3.729; e. vs. ISC þ C50, q ¼ 4.799. Hilus: a. vs. SO, q ¼ 24.43; b. vs. ISC þ C25,
q ¼ 31.30; c. vs. ISC þ C50, q ¼ 31.59; d. vs. SO, q ¼ 6.867; e. vs, SO, q ¼ 7.162 (One-way ANOVA and NewmaneKeuls as the post hoc test).
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